NOVARTIS' eye care division Alcon has announced the acquisition of US-based PowerVision Inc, a privately-held firm focused on creating "fluid-based intraocular lens implants".
The PowerVision technology, used in cataract surgery, creates a continuously variable monofocal lens by utilising the natural contraction of eye muscles.
The deal is worth US$285 million, plus additional payments based on specific regulatory and commercial milestones starting in 2023.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Mar 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Mar 19
